Skip to main content
. Author manuscript; available in PMC: 2020 Sep 19.
Published in final edited form as: Anesthesiology. 2020 May;132(5):981–991. doi: 10.1097/ALN.0000000000003176

Table 5.

Summary Statistics for Outcome Measures across the Three Cohorts with the P Values for the Change Points in the Corresponding Regression Models

Cohort 1 Cohort 2 Cohort 3 P Value Change (2 mg→1 mg) P Value Change (1 mg→2 mg)
Hydromorphone (binary) 2,183 (21.2%) 296 (10.3%) 226 (16.6%) < 0.0001 0.008
Hydromorphone, mg 0.8 (0.6) 0.7 (0.5) 0.8 (0.7) < 0.0001 0.008
PACU morphine milligram equivalents 15.6 ± 21.5 15.6 ± 21.9 15.6 ± 25.7 0.106 0.784
Intraoperative morphine milligram equivalents 38.7 ± 25.8 35.7 ± 24.8 34.22 ± 24.8 0.984 0.238
Intraoperative fentanyl, mcg 145.9 ± 111.4 139.0 ± 115.2 126.6 ± 104.5 0.245 0.111
Total encounter morphine milligram equivalents 54.2 ± 36.1 51.3 ± 36.6 49.8 ± 38.2 0.320 0.513
Admission PACU pain score 3.1 ± 3.7 3.5 ± 3.8 3.4 ± 3.7 0.316 0.068
Discharge PACU pain score 2.6 ± 2.6 2.8 ± 2.7 2.6 ± 2.7 0.536 0.214

Summary statistics for the outcome measures are reported for each of the three cohorts. Cohorts 1 and 3 refer to the time periods with a 2-mg unit dose presentation, and cohort 2 refers to the time period with a 1-mg unit dose presentation. Continuous variables are presented as mean ± SD, and categorical variables are presented as number (percentage). Hydromorphone (binary) represents the proportion of patients who were administered greater than 1 mg of hydromorphone intraoperatively. For each outcome variable, the P values for the change-points in the segmented regression models are provided. PACU, postanesthesia care unit.